Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD

Gut

Volumn 65, Issue 10, 2016, Pages 1681-1689

  Sabino, Jõo ^a   Vieira Silva, Sara ^b,c   Machiels, Kathleen ^a   Joossens, Marie ^b,c,d   Falony, Gwen ^b,c   Ballet, Vera ^a   Ferrante, Marc ^a   Van Assche, Gert ^a   Van Der Merwe, Schalk ^e   Vermeire, Severine ^a   Raes, Jeroen ^b,c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DNA 16S; URSODEOXYCHOLIC ACID; ALKALINE PHOSPHATASE; CHOLAGOGUE;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DNA SEQUENCE; DYSBIOSIS; ENTEROCOCCUS; FECES ANALYSIS; FEMALE; FUSOBACTERIUM; HUMAN; INTESTINE FLORA; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; ULCERATIVE COLITIS; VALIDATION STUDY; AGED; ANTAGONISTS AND INHIBITORS; BIOPSY; COLONOSCOPY; FECES; INFLAMMATORY BOWEL DISEASE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SCLEROSING CHOLANGITIS; SEVERITY OF ILLNESS INDEX; STATISTICS;

ADULT; AGED; ALKALINE PHOSPHATASE; BIOPSY; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; COLONOSCOPY; DYSBIOSIS; ENTEROCOCCUS; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; URSODEOXYCHOLIC ACID;

EID: 84970044586     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-311004     Document Type: Article

References (40)

1. Hirschfield GM, Karlsen TH, Lindor KD, et al. Primary sclerosing cholangitis. Lancet 2013;382:1587-99.
2. Alabraba E, Nightingale P, Gunson B, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009;15:330-40.
3. Olsson R, Björnsson E, Bäckman L, et al. Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. J Hepatol 1998;28:426-32.
4. Färkkilä M, Karvonen AL, Nurmi H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004;40:1379-86.
5. Seidel D, Eickmeier I, Kühl AA, et al. CD8T cells primed in the gut-Associated lymphoid tissue induce immune-mediated cholangitis in mice. Hepatology 2014;59:601-11.
6. Tabibian JH, O?Hara SP, Trussoni CE, et al. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology 2016;63:185-96.
7. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014;146:1489-99.
8. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008;105:16731-6.
9. Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn?s disease and their unaffected relatives. Gut 2011;60:631-7.
10. Willing BP, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 2010;139:1844-54.e1.
11. Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014;63:1275-83.
12. Lindor KD, Kowdley KV, Harrison ME. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol 2015;110:646-59.
13. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012;6:965-90.
14. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn?s disease: Definitions and diagnosis. J Crohns Colitis 2010;4:7-27.
15. Kozich JJ, Westcott SL, Baxter NT, et al. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol 2013;79:5112-20.
16. Magoč T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics 2011;27:2957-63.
17. Edgar RC, Haas BJ, Clemente JC, et al. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 2011;27:2194-200.
18. Wang Q, Garrity GM, Tiedje JM, et al. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 2007;73:5261-7.
19. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 2010;26:2460-1.
20. Eren AM, Maignien L, Sul WJ, et al. Oligotyping: Differentiating between closely related microbial taxa using 16S rRNA gene data. Methods Ecol Evol 2013;4:1111-9.
21. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS ONE 2013;8:e61217.
22. Tickle TWL, Yiren Lu, Huttenhower C. Multivariate association of microbial communities with rich metadata in high-dimensional studies. (In progress
23. Hall M, Frank E, Holmes G, et al. The WEKA data mining software: an update. ACM SIGKDD Explorations Newsletter 2009;11:10-18.
24. Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014;513:59-64.
25. Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011;54:562-72.
26. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn?s disease. Cell Host Microbe 2014;15:382-92.
27. Fisher K, Phillips C. The ecology, epidemiology and virulence of Enterococcus. Microbiology 2009;155(Pt 6):1749-57.
28. Strauss J, Kaplan GG, Beck PL, et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis 2011;17:1971-8.
29. Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012;22:292-8.
30. Rossen NG, Fuentes S, Boonstra K, et al. The mucosa-Associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. J Crohns Colitis 2015;9:342-8.
31. Al Mamari S, Djordjevic J, Halliday JS, et al. Improvement of serum alkaline phosphatase to 1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2013;58: 329-34.
32. Lindström L, Hultcrantz R, Boberg KM, et al. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2013;11:841-6.
33. Pohl J, Ring A, Stremmel W, et al. The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2006;18:69-74.
34. Steck N, Hoffmann M, Sava IG, et al. Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. Gastroenterology 2011;141:959-71.
35. Kwon W, Jang JY, Kim EC, et al. Changing trend in bile microbiology and antibiotic susceptibilities: over 12 years of experience. Infection 2013;41:93-102.
36. Kummen M, Holm K, Anmarkrud JA, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut Published Online First: 17 Feb 2016. doi:10.1136/gutjnl-2015-310500
37. Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013;58:2045-55.
38. Ott C, Scholmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 2013;10:585-95.
39. Liu JZ, Hov JR, Folseraas T, et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 2013;45:670-5.
40. Wacklin P, Tuimala J, Nikkilä J, et al. Faecal microbiota composition in adults is associated with the FUT2 gene determining the secretor status. PLoS ONE 2014;9: e94863.